Intellia Therapeutics, Inc. insider trading
Every open-market purchase and sale by Intellia Therapeutics, Inc.'s officers, directors and largest shareholders since November 4, 2021, and what the share price did next.
| Date | Insider | Trade | Shares | Price | Value | 1M after | 3M after | 6M after |
|---|
Does following Intellia Therapeutics, Inc.’s insiders pay?
From March 13, 2017 to October 6, 2026, 17 insiders reported 3 open-market purchases and 54 sales not made under a pre-set plan in Intellia Therapeutics, Inc. Twelve months after each purchase was reported, the shares were −13.9% against the S&P 500 on average (median −13.9%), over 2 purchases with a full year of prices; 0% beat the index. After sales, the shares moved −29.2% against the index over 12 months (a negative figure means selling was the right call). That rests on fewer than 20 purchases, too few to read much into. Buying each purchase the day after it was reported, an equal amount each, held 12 months or until that insider reported a sale, would have turned $10,000 on March 13, 2019 into $8,308 by November 2, 2026, −2.4% a year. It held shares 29% of the time; the S&P 500 on those same days, with Treasury bills otherwise, made $13,583 (+4.1% a year), and held throughout $30,132 (+15.6%).
| Insider | Role | Purchases | 12 months after their purchases | Beat the S&P 500 | Sales | 12 months after their sales | Latest report |
|---|---|---|---|---|---|---|---|
| Basta James | EVP, General Counsel | 0 | — | — | 8 | −43.6% (6) | March 3, 2026 |
| Clark Eliana | EVP, Chief Technical Officer | 0 | — | — | 7 | −46.0% (6) | January 7, 2026 |
| Dube Michael P | VP, Chief Accounting Officer | 0 | — | — | 7 | −4.6% (4) | October 6, 2026 |
| Leonard John M | President and CEO | 0 | — | — | 6 | −32.0% (5) | January 7, 2026 |
| Lebwohl David | EVP, Chief Medical Officer | 0 | — | — | 5 | −46.9% (4) | January 7, 2026 |
| Formela Jean Francois | Director | 0 | — | — | 4 | +37.0% (4) | March 1, 2021 |
| Dulac Edward J III | EVP, Chief Financial Officer | 0 | — | — | 3 | −33.4% (1) | July 24, 2026 |
| Goddard Glenn | EVP, Chief Financial Officer | 0 | — | — | 3 | −54.4% (3) | January 5, 2024 |
| Hicks Derek | EVP, Chief Business Officer | 0 | — | — | 3 | −51.8% (3) | January 7, 2025 |
| Sepp-Lorenzino Laura | EVP, Chief Scientific Officer | 0 | — | — | 3 | −47.4% (3) | January 7, 2025 |
| Schiermeier Andrew | EVP, Chief Operating Officer | 1 | −23.1% (1) | 0% | 1 | +27.8% (1) | January 5, 2021 |
| Caribou Biosciences, Inc. | 10% owner | 0 | — | — | 1 | −43.0% (1) | January 30, 2018 |
| Chase William J | Director | 1 | −4.7% (1) | 0% | 0 | — | August 22, 2025 |
| Cohen Fred E | Director | 1 | — | — | 0 | — | January 7, 2026 |
| Novartis Institutes For Biomedical Research, Inc. | 10% owner | 0 | — | — | 1 | −17.6% (1) | December 14, 2017 |
| Rivera Jose E | EVP, General Counsel | 0 | — | — | 1 | +27.8% (1) | January 5, 2021 |
| Schultes Birgit C | EVP, Chief Scientific Officer | 0 | — | — | 1 | — | January 7, 2026 |
When several insiders traded Intellia Therapeutics, Inc.
Months when 2 or more insiders became net buyers, or 3 or more net sellers, of Intellia Therapeutics, Inc. in reports dated in the 91 days before the month end, and how the stock did against the S&P 500 from that month end. After 7 selling crowds, +9.4%. One company's history is too short to judge by; the test across every company is the better guide.
| Month | Crowd | 3 months on, vs S&P 500 | 6 months | 12 months |
|---|---|---|---|---|
| January 30, 2026 | 7 selling | −3.6% | −28.2% | not yet |
| July 31, 2025 | 3 selling | +3.7% | +2.9% | −28.7% |
| January 31, 2025 | 7 selling | −8.8% | +11.9% | +10.5% |
| January 31, 2024 | 7 selling | −9.5% | −7.6% | −85.3% |
| January 31, 2023 | 6 selling | −14.3% | −18.0% | −62.7% |
| March 31, 2022 | 4 selling | −10.5% | −2.7% | −41.5% |
| January 29, 2021 | 3 selling | +9.5% | +107.3% | +16.4% |